Reversing Hyperammonemia in Neuroendocrine Tumors
Authors:
- Amanda TownsendATAmanda Townsend
- Kenneth PittmanKPKenneth Pittman
- Richard KimberRKRichard Kimber
- William PattersonWPWilliam Patterson
- Shawgi SukumaranSSShawgi Sukumaran
- Timothy J. PriceTPTimothy J. Price
- 1 September 2010
- journal article
- case report
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 44 (8) , e186-e189
Abstract
Ammonia is a neurotoxin that is normally cleared by the intact liver and if not, hyperammonemia results in hepatic encephalopathy. Hyperammonemia may be owing to primary or secondary causes. Early diagnosis is important to prevent permanent brain damage. Advanced malignancy involving the liver is associated with hyperammonemia as a result of abnormality of the portal venous system or massive hepatic tumor burdon. Neuroendocrine tumors are an example of a malignant process that frequently involves the liver but despite this, may still have a relatively good prognosis, and are often characterized by chronic manageable symptoms and slow progression. Hyperammonemia in neuroendocrine tumor would represent a potentially reversible but ongoing process associated with an indolent malignancy. We present 2 cases that are examples of this diagnosis and discuss the diagnostic and management issues that may arise.Keywords
This publication has 10 references indexed in Scilit:
- Resolution of Hepatic Encephalopathy Following Hepatic Artery Embolization in a Patient with Well-Differentiated Neuroendocrine Tumor Metastatic to the LiverCardioVascular and Interventional Radiology, 2009
- Hyperammonemic encephalopathy in a patient with primary hepatic neuroendocrine carcinomaMedical Oncology, 2008
- Valproate-Induced Hyperammonemic Encephalopathy Treated by HemodialysisRenal Failure, 2008
- Hyperammonemia encephalopathy: An important cause of neurological deterioration following chemotherapyLeukemia & Lymphoma, 2007
- Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumorsCancer, 2005
- Doxorubicin and Streptozotocin After Failed Biotherapy of Neuroendocrine TumorsJournal of Gastrointestinal Cancer, 2005
- Unusual causes of hyperammonemia in the EDThe American Journal of Emergency Medicine, 2004
- Hyperammonemia in urea cycle disorders: Role of the nephrologistAmerican Journal of Kidney Diseases, 2001
- Chemoembolization of Hepatic Neoplasms: Safety, Complications, and When to WorryRadioGraphics, 1999
- Sodium Benzoate in the Treatment of Acute Hepatic Encephalopathy: A Double–Blind Randomized TrialHepatology, 1992